Clinically Validated Probiotics
Why Sustainable Biomanufacturing Must Start Earlier in The Process
From Snapshots to Movies
Maximising Patient Engagement in Clinical Trials
Beyond Reporting - Safety surveillance analytics for medical devices...
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Hallucinations to Evidence: LLMs clinicians can finally trust
Research Fellow, Institute of Health Informatics, University College London
Jinge Wu is a Research Fellow at the UCL Institute of Health Informatics specialising in multimodal large language models for clinical decision support and medical AI She has led research projects funded by UKRI MRC and Health Data Research UK working with largescale NHS electronic health record data to develop capable reliable and explainable AI for realworld clinical applications Her research ha...
Articles
The Rapidly Evolving Landscape of Cancer Therapeutics
Cancer is considered as a common name to address a large group comprising more than diseases affecting several parts of the body All cancers show common characteristics such as the uncontrolled growth and proliferation of abnormal cells
Research Insights
The Shape of Waning Vaccinal Immunity: Implications For Control
The COVID pandemic and current uncertainties about HN influenza underscore the importance of vaccination for both community immunity and to prevent pathogen invasion While the duration of a fullyimmune period
Case Studies
Tablet Coating at Low Bed Temperatures with a Novel Coating Polymer
This study shows how to obtain elegant uniform coatings with zero visible defects and a practical coating solution for heat sensitive products For More Infromation Click Here
Techno Trends
Armata Pharmaceuticals Introduces Breakthrough AP-SA02 Therapy for Treating S. aureus Bacteremia
Armata Pharmaceuticals has introduced APSA for the adjunct treatment of complicated Staphylococcus aureus S aureus bacteremia caused by methicillinsensitive S aureus MSSA or methicillinresistant S aureus MRSA
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Application of Artificial Intelligence in Development Safety Update Report Preparation
Maria Carolina Braga holds a degree in Pharmaceutical Sciences with a specialization in Clinical Pharmacy. She has over 10 years of experience in pharmacovigilance and recently completed a master’s degree in Pharmacovigilance and Pharmacoepidemiology, focusing her research on the use of artificial intelligence in aggregate safety report writing.
Envisioning the Biomanufacturing Facility of the Future
Merrilee is the Head of the BioContinuum™ Platform, driving the strategy and execution of Process Intensification Technologies, Software & Automation, and Analytics to meet the needs of biologics manufacturers. Throughout her 15 years at MilliporeSigma, she managed multiple product lines including clarification, aseptic, virus filtration, and Single Use & Systems.
Advanced Drug Delivery Systems for Chronic Liver Disease Management
Jyothi U Menon received her PhD in Biomedical Engineering from the University of Texas (UT) Arlington and UT Southwestern Medical Center joint program. She completed her postdoctoral training at the University of Oxford, UK. She is currently an Associate Professor in the College of Pharmacy at the University of Rhode Island where her research focus is on targeted drug delivery systems to treat lung and liver diseases, and in vitro disease modeling.
Labelling and imaging of Radiopharmaceuticals
Sumel Ashique has been working as an assistant professor in Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India. He has 3.5 years of teaching experience. He has achieved 50+ publications of International and national accredited reputed journals (Scopus, UGC). He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 4 granted patents from IP and Australia, 8 published book chapters in International Books and 12 book chapters have been submitted to well-known publishers like Springer, Elsevier, Bentham and Taylor & Francis. Currently he is editing 5 books under CRC; AAP, Springer and Wiley publisher
Radheshyam Pal is an Assistant Professor at Pandaveswar School of Pharmacy. His areas of expertise in Neuropharmacology. He specifically works on the role of natural products in the CNS. He has 2 years of teaching experience. He has 2 patents and also 10 book chapters submitted in international publisher.
QSAR - Changing the Landscape of Antidiabetic Drug Discovery
Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India. Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.
press releasesRead more...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
Enhertu approved in the EU as adjuvant treatment for patients with residual disease after neoadjuvant treatment for HER2-positive early breast cancer
AstraZeneca and Daiichi Sankyos Enhertu trastuzumab deruxtecan has been approved in the European Union EU as a monotherapy for the adjuvant treatment of adult patients with resected HERpositive breast cancer who have residual invasive disease after neoadjuvant taxanebased and HERtargeted treatment
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Teva Pharmaceuticals International GmbH a subsidiary of Teva Pharmaceutical Industries Ltd today announced that it has completed the acquisition of assets from BioXcel Therapeutics Inc including worldwide rights to BXCL BXCL is an investigational dexmedetomidine
EventsRead more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
Pfizer’s TALZENNA Plus XTANDI Approved for Earlier Treatment of Metastatic Prostate Cancer
Pfizer has received approval from the US Food and Drug Administration FDA to expand the use of TALZENNA talazoparib in combination with XTANDI enzalutamide for men with metastatic prostate cancer that is sensitive to hormone treatment and has specific homologous recombination repair HRR gene mutatio...
Okomera Signs Agreement with Servier for Cancer Research Technology
Okomera has signed a commercial agreement with Servier to support the development of new cancer treatments using its tumour miniaturisation technology More than of oncology drug candidates fail to reach the market making it important to identify promising treatments at an early stage Okomeras platf...
